Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets EXMKT - Delayed Quote USD

Ampio Pharmaceuticals, Inc. (AMPE)

Compare
0.0006
-0.0202
(-97.12%)
At close: April 2 at 4:00:00 PM EDT
Loading Chart for AMPE
  • Previous Close 0.0208
  • Open 0.0208
  • Bid 0.0401 x 900
  • Ask 0.4000 x 800
  • Day's Range 0.0208 - 0.0208
  • 52 Week Range 0.0001 - 0.9656
  • Volume 9
  • Avg. Volume 166
  • Market Cap (intraday) 681
  • Beta (5Y Monthly) 3.71
  • PE Ratio (TTM) --
  • EPS (TTM) -10.6600
  • Earnings Date Apr 3, 2025 - Apr 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.

ampiopharma.com

6

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AMPE

View More

Performance Overview: AMPE

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMPE
76.92%
S&P 500 (^GSPC)
3.58%

1-Year Return

AMPE
99.93%
S&P 500 (^GSPC)
8.94%

3-Year Return

AMPE
100.00%
S&P 500 (^GSPC)
24.75%

5-Year Return

AMPE
100.00%
S&P 500 (^GSPC)
124.42%

Compare To: AMPE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMPE

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    681.00

  • Enterprise Value

    -3.81M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.00

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -61.57%

  • Return on Equity (ttm)

    -113.96%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -8.63M

  • Diluted EPS (ttm)

    -10.6600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.12M

  • Total Debt/Equity (mrq)

    13.42%

  • Levered Free Cash Flow (ttm)

    -5.37M

Research Analysis: AMPE

View More

Company Insights: AMPE

Research Reports: AMPE

View More

People Also Watch